Literature DB >> 27672025

Monocrotaline-Induced Pulmonary Hypertension Involves Downregulation of Antiaging Protein Klotho and eNOS Activity.

Rohan Varshney1, Quaisar Ali1, Chengxiang Wu1, Zhongjie Sun2.   

Abstract

The objective of this study is to investigate whether stem cell delivery of secreted Klotho (SKL), an aging-suppressor protein, attenuates monocrotaline-induced pulmonary vascular dysfunction and remodeling. Overexpression of SKL in mesenchymal stem cells (MSCs) was achieved by transfecting MSCs with lentiviral vectors expressing SKL-green fluorescent protein (GFP). Four groups of rats were treated with monocrotaline, whereas an additional group was given saline (control). Three days later, 4 monocrotaline-treated groups received intravenous delivery of nontransfected MSCs, MSC-GFP, MSC-SKL-GFP, and PBS, respectively. Ex vivo vascular relaxing responses to acetylcholine were diminished in small pulmonary arteries (PAs) in monocrotaline-treated rats, indicating pulmonary vascular endothelial dysfunction. Interestingly, delivery of MSCs overexpressing SKL (MSC-SKL-GFP) abolished monocrotaline-induced pulmonary vascular endothelial dysfunction and PA remodeling. Monocrotaline significantly increased right ventricular systolic blood pressure, which was attenuated significantly by MSC-SKL-GFP, indicating improved PA hypertension. MSC-SKL-GFP also attenuated right ventricular hypertrophy. Nontransfected MSCs slightly, but not significantly, improved PA hypertension and pulmonary vascular endothelial dysfunction. MSC-SKL-GFP attenuated monocrotaline-induced inflammation, as evidenced by decreased macrophage infiltration around PAs. MSC-SKL-GFP increased SKL levels, which rescued the downregulation of SIRT1 (Sirtuin 1) expression and endothelial NO synthase (eNOS) phosphorylation in the lungs of monocrotaline-treated rats. In cultured endothelial cells, SKL abolished monocrotaline-induced downregulation of eNOS activity and NO levels and enhanced cell viability. Therefore, stem cell delivery of SKL is an effective therapeutic strategy for pulmonary vascular endothelial dysfunction and PA remodeling. SKL attenuates monocrotaline-induced PA remodeling and PA smooth muscle cell proliferation, likely by reducing inflammation and restoring SIRT1 levels and eNOS activity.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  Klotho protein; SIRT1 protein, human; familial primary pulmonary hypertension; genetic therapy; mesenchymal stromal cells

Mesh:

Substances:

Year:  2016        PMID: 27672025      PMCID: PMC5063703          DOI: 10.1161/HYPERTENSIONAHA.116.08184

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  50 in total

1.  Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome.

Authors:  Alain Chapel; Jean Marc Bertho; Morad Bensidhoum; Loic Fouillard; Randell G Young; Johanna Frick; Christelle Demarquay; Frédérique Cuvelier; Emilie Mathieu; François Trompier; Nicolas Dudoignon; Claire Germain; Christelle Mazurier; Jocelyne Aigueperse; Jade Borneman; Norbert Claude Gorin; Patrick Gourmelon; Dominique Thierry
Journal:  J Gene Med       Date:  2003-12       Impact factor: 4.565

Review 2.  Interactions of mesenchymal stem cells with endothelial cells.

Authors:  Seyed Mahdi Nassiri; Reza Rahbarghazi
Journal:  Stem Cells Dev       Date:  2013-11-28       Impact factor: 3.272

3.  Shear stress, SIRT1, and vascular homeostasis.

Authors:  Zhen Chen; I-Chen Peng; Xiaopei Cui; Yi-Shuan Li; Shu Chien; John Y-J Shyy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats.

Authors:  Kiyoko Takemiya; Hisashi Kai; Hideo Yasukawa; Nobuhiro Tahara; Seiya Kato; Tsutomu Imaizumi
Journal:  Basic Res Cardiol       Date:  2009-10-17       Impact factor: 17.165

Review 5.  Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.

Authors:  Sudhir H Ranganath; Oren Levy; Maneesha S Inamdar; Jeffrey M Karp
Journal:  Cell Stem Cell       Date:  2012-03-02       Impact factor: 24.633

6.  Mesenchymal stem cells attenuate vascular remodeling in monocrotaline-induced pulmonary hypertension rats.

Authors:  Jiang Xie; Dayi Hu; Lili Niu; Suping Qu; Shenghao Wang; Shuang Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

7.  The Antiaging Gene Klotho Regulates Proliferation and Differentiation of Adipose-Derived Stem Cells.

Authors:  Jun Fan; Zhongjie Sun
Journal:  Stem Cells       Date:  2016-02-26       Impact factor: 6.277

8.  Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.

Authors:  Soban Umar; Yvonne P de Visser; Paul Steendijk; Cindy I Schutte; El Houari Laghmani; Gerry T M Wagenaar; Wilhelmina H Bax; Eleni Mantikou; Daniel A Pijnappels; Douwe E Atsma; Martin J Schalij; Ernst E van der Wall; Arnoud van der Laarse
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-25       Impact factor: 4.733

9.  AAV-based RNAi silencing of NADPH oxidase gp91(phox) attenuates cold-induced cardiovascular dysfunction.

Authors:  Xiuqing Wang; Lucille Skelley; Bo Wang; Ayesha Mejia; Val Sapozhnikov; Zhongjie Sun
Journal:  Hum Gene Ther       Date:  2012-08-13       Impact factor: 5.695

10.  Antiaging Gene Klotho Attenuates Pancreatic β-Cell Apoptosis in Type 1 Diabetes.

Authors:  Yi Lin; Zhongjie Sun
Journal:  Diabetes       Date:  2015-09-04       Impact factor: 9.461

View more
  17 in total

1.  Pluripotent hematopoietic stem cells augment α-adrenergic receptor-mediated contraction of pulmonary artery and contribute to the pathogenesis of pulmonary hypertension.

Authors:  Ryota Hashimoto; Gregg M Lanier; Vidhi Dhagia; Sachindra R Joshi; Allan Jordan; Ian Waddell; Rubin Tuder; Kurt R Stenmark; Michael S Wolin; Ivan F McMurtry; Sachin A Gupte
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-01-08       Impact factor: 5.464

Review 2.  Stem cell therapy for pulmonary arterial hypertension: An update.

Authors:  Qiwei Wilton Sun; Zhongjie Sun
Journal:  J Heart Lung Transplant       Date:  2022-03-06       Impact factor: 13.569

3.  Cord blood alpha klotho is decreased in small for gestational age preterm infants with placental lesions of accelerated aging.

Authors:  Andrew D Franklin; Juanita Saqibuddin; Kelli Stephens; Robert Birkett; Lily Marsden; Linda M Ernst; Karen K Mestan
Journal:  Placenta       Date:  2019-08-30       Impact factor: 3.481

4.  Secreted Klotho Attenuates Inflammation-Associated Aortic Valve Fibrosis in Senescence-Accelerated Mice P1.

Authors:  Jianglei Chen; Jun Fan; Shirley Wang; Zhongjie Sun
Journal:  Hypertension       Date:  2018-03-26       Impact factor: 10.190

5.  Epigenetic Regulation of KL (Klotho) via H3K27me3 (Histone 3 Lysine [K] 27 Trimethylation) in Renal Tubule Cells.

Authors:  Xiaobin Han; Zhongjie Sun
Journal:  Hypertension       Date:  2020-03-30       Impact factor: 10.190

6.  Klotho Deficiency Causes Heart Aging via Impairing the Nrf2-GR Pathway.

Authors:  Kai Chen; Shirley Wang; Qiwei Wilton Sun; Bo Zhang; Mujib Ullah; Zhongjie Sun
Journal:  Circ Res       Date:  2020-12-18       Impact factor: 17.367

7.  Regenerative Medicine Application of Mesenchymal Stem Cells.

Authors:  Figen Abatay Sel; Fatma Savran Oguz
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

8.  In Vivo Cardiac-specific Expression of Adenylyl Cyclase 4 Gene Protects against Klotho Deficiency-induced Heart Failure.

Authors:  Kai Chen; Shirley Wang; Zhongjie Sun
Journal:  Transl Res       Date:  2022-01-31       Impact factor: 10.171

9.  Induction of anti-aging gene klotho with a small chemical compound that demethylates CpG islands.

Authors:  Dongju Jung; Yuechi Xu; Zhongjie Sun
Journal:  Oncotarget       Date:  2017-07-18

10.  Activation of DNA demethylases attenuates aging-associated arterial stiffening and hypertension.

Authors:  Kai Chen; Zhongjie Sun
Journal:  Aging Cell       Date:  2018-04-16       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.